Antiplatelet vs R-tPA for Acute Mild Ischemic Stroke
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 760 participants.
Also called NCT03661411
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 760 participants
- Registry
-
NCT03661411
-
- Other papers using this trial's data
- Dual Antiplatelet Therapy Versus Alteplase for Mild Stroke with Admission NIHSS Score 0-3 Versus 4-5: A Secondary Analysis of the ARAMIS Randomized Trial
- Dual Antiplatelet Therapy vs Alteplase for Patients With Minor Nondisabling Acute Ischemic Stroke: The ARAMIS Randomized Clinical Trial
- Dual Antiplatelet Versus Alteplase for Early Neurologic Deterioration in Minor Stroke With Versus Without Large Vessel Occlusion: Prespecified Post Hoc Analysis of the ARAMIS Trial
- Onset to Treatment Time and Early Neurological Deterioration of Dual Antiplatelet Therapy Versus Alteplase in Minor Stroke
- Systolic blood pressure and early neurological deterioration in minor stroke: A post hoc analysis of ARAMIS trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03661411. Randomized; no masking; primary purpose treatment. Start 2018-10-17 (actual); primary completion 2022-07-18 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Antiplatelet vs R-tPA for Acute Mild Ischemic Stroke
- Acronym
- ARAMIS
- Condition
- Stroke
- Intervention (Drug)
- Aspirin
- Intervention (Drug)
- Clopidogrel 75mg
- Intervention (Drug)
- Alteplase
- Lead sponsor
- General Hospital of Shenyang Military Region
Record details
- Record id
cardio:ct-nct03661411- Content hash
094a152342f1e6e6847db22982abeb690811a1407a972ed2db2d3d8fa60392a2